Business
Guardant Health Announces Collaboration with Trial Library to Increase Access to Cancer Clinical Trials Across the U.S.
Partnership integrates Guardant’s large-scale genomic data with Trial Library’s AI-powered matching and navigation platform to expand equitable access to
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nPartnership integrates Guardant’s large-scale genomic data with Trial Library’s AI-powered matching and navigation platform to expand equitable access to oncology clinical trials across the United States\n\n\nCollaboration seeks to broaden trial access for representative and underserved patient populations by uniting genomic insights with personalized navigation and support services\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health (Nasdaq: GH), a leading precision oncology company, and Trial Library, an AI technology company enabling oncology clinical trials as a care option, today announced a strategic collaboration to increase access to cancer clinical trials in the United States.\n\nThe collaboration combines Guardant Health’s suite of cutting-edge precision oncology diagnostics with Trial Library’s AI-powered matching and patient navigation platform. Together, the companies aim to streamline the identification, referral, and enrollment of patients into precision oncology clinical trials, helping providers offer new treatment opportunities to a broader and more representative patient population.\n\nGuardant’s comprehensive real-world data capabilities, powered by a growing platform of more than 1 million patients tested, will help identify relevant patients for clinical trials based on biomarker and clinical data. Trial Library's platform unlocks access to clinical trials in community-based clinical settings across more than 320 clinics and 1,500 providers nationwide through AI-enabled provider activation, compliant eligible patient identification and longitudinal navigation throughout the trial lifecycle. The partnership addresses the needs of both patients and their care providers, enabling remote clinical eligibility verification and robust patient-centric navigation at the right time.\n\n“Precision oncology only works if patients can actually access the treatments being developed,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “With Trial Library, we’re linking biomarker insights directly to real trial opportunities and providing the support patients need to act on them. Together, we can close the gap between genomic discovery and equitable participation in lifesaving research.”\n\nMore than 70 percent of patients1 are open to participating in clinical trials, yet fewer than 7 percent with cance...